Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
55 results about "Sialyl LeA" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
RM2 antigen (beta1,4-GalNAc-disialyl-Lc4) as prostate cancer-associated antigen
InactiveUS20050221397A1Useful predictionBiological material analysisBiological testingAntigenSerum ige
A novel carbohydrate antigen, β1,4-GalNAc-disialyl-Lc4, defined by monoclonal antibody RM2, is expressed in human prostate cancer, but not in benign prostate hypertrophy (BPH) or normal prostate gland. Monoclonal antibody RM2 or other antibodies with similar specificity are useful for diagnosis of prostate cancer by immunohistology of biopsy samples, specifications from a total prostatectomy, and quantitative determination of RM2 antigen in sera of patients.
Owner:NORTHERN ADVANCEMENT CENT FOR SCI & TECH
Antibodies with immune effector activity and that internalize in endosialin-positive cells
ActiveUS20060239911A1Improve anti-tumor activityEnhanced antibody-dependent cellular cytotoxicityNanomedicineImmunoglobulins against cell receptors/antigens/surface-determinantsDiseaseNucleotide
This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing endosialin and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to endosialin-expressing cells as well as in eliciting an immune-effector activity particularly on tumor and neovascular cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer and neovascular cells; and methods of treating cancer and neovascular disease using the antibodies, derivatives and fragments.
Owner:EISAI INC
Compositions and methods for detecting cancer
InactiveUS20110177614A1Facilitating tumor progressionReduce in quantitySugar derivativesImmunoglobulins against animals/humansAntiendomysial antibodiesSialyl LeA
The invention provides sialylated glycans and antibodies that specifically bind to them. The invention's compositions and methods for using them are useful for early detection and diagnosis of cancer.
Owner:SEATTLE GENETICS INC +2
Methods and compositions for screening and detecting biomarkers
InactiveUS20150309028A1Altered glycosylation patternImmunoglobulins against animals/humansDisease diagnosisParanasal Sinus CarcinomaHuman tumor
The present invention is concerned with a novel antigens associated with human tumors, including carcinomas of the colon or lung, as well as novel monoclonal antibodies which specifically bind to said antigen. The antibodies bind to normal human cells to a much lesser degree than to tumor cells. The antigens include 100 kDa glycoprotein that has a colorectal cancer membrane bound and a soluble form, has a UV absorbance peak at about 228 nm, an isoelectric point of about 3.5 to 4, a sialic acid content of about 20%, and does not substantially bind to an antibody specific for ACT. The antibodies find use both in methods such as the detection of malignant cells associated with tumors and in monitoring therapeutic treatment of humans with tumors.
Owner:EDP BIOTECH
Bird's-nest enzyme linked immunosorbent assay kit
InactiveCN102621329AIn favor of legitimate rights and interestsImprove accuracyBiological testingAbzymeElisa kit
The invention provides a bird's-nest enzyme linked immunosorbent assay kit, which comprises sialoglycoprotein standard liquid, a sialoglycoprotein antibody, an enzyme-labeled secondary antibody, an ELISA plate and substrate color development liquid. The bird's-nest enzyme linked immunosorbent assay kit can be used for quantitatively testing bird's-nests and relevant products of the bird's-nest, and is wide in application range, fine in specificity, high in sensitivity and fine in matrix interference resistant effect, accuracy of detection results and repeatability and low in detection cost, and field detection and screening of large quantities of samples can be carried out conveniently.
Owner:SHENZHEN ACAD OF METROLOGY & QUALITY INSPECTION
Self-priming polysialyltransferase
The invention relates to a fusion protein comprising a bifunctional sialytransferase and a poly-sialytransferase and methods to use the fusion proteins for production of poly-sialylated end products, e.g. oligosaccharides and glycoproteins.
Owner:NAT RES COUNCIL OF CANADA
Antibodies with immune effector activity and that internalize in endosialin-positive cells
ActiveUS7615372B2NanomedicineImmunoglobulins against cell receptors/antigens/surface-determinantsDiseaseNucleotide
This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing endosialin and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to endosialin-expressing cells as well as in eliciting an immune-effector activity particularly on tumor and neovascular cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer and neovascular cells; and methods of treating cancer and neovascular disease using the antibodies, derivatives and fragments.
Owner:EISAI INC
Anti-cd19 antibody having adcc and cdc functions and improved glycosylation profile
ActiveUS20130224190A1Interesting and valuable glycosylation profileLower levelAnimal cellsPeptide librariesFucoseMannose
The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and / or a high oligomannose level and low level of sialylated glycoform. The present invention also relates to the use of these antibodies in the treatment, prevention or management of disease or disorder, such as cancer, especially a B-cell malignancy, and auto-immune disease.
Owner:INT DRUG DEV BIOTECH
Chimeric antigen receptor
Provision of a chimeric antigen receptor (CAR) comprising a disialoganglioside (GD2)-binding domain which comprises a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: b) a light chain variable region (VL) having CDRs with the following sequences: T cells expressing such a CAR are useful in the treatment of some cancers.
Owner:AUTOLUS LIMIED
Quantitative control of sialylation and specific mono-sialylation
ActiveUS9481902B2Microbiological testing/measurementImmunoglobulinsSialic acid aldolaseControl manner
The present disclosure is directed to the use of certain glycosyltransferase variants having N-terminal truncation deletions. It was found that the combination of two different truncation variants of human β-galactoside-α-2,6-sialyltransferase I (hST6Gal-I) exhibited different specific sialyltransferase enzymatic activities. In one example, under conditions wherein the first variant Δ89 hST6Gal-I catalyzed formation of bi-sialylated target molecules the second variant Δ108 hST6Gal-I catalyzed formation of mono-sialylated target molecules. Thus, disclosed are variants of mammalian glycosyltransferase, nucleic acids encoding the same, methods and means for recombinantly producing the variants of mammalian glycosyltransferase and use thereof, particularly for sialylating in a quantitatively controlled manner terminal acceptor groups of glycan moieties being part of glycoproteins such as immunoglobulins.
Owner:ROCHE DIAGNOSTICS OPERATIONS INC
Humanized antibody and application thereof
ActiveCN114031688AGrowth inhibitionPrevent invasionColon cancer vaccineAntibody ingredientsHumanized antibodySignal Pathways
The invention discloses a humanized antibody and application thereof, the humanized antibody comprises a heavy chain variable region and a light chain variable region, and can specifically target a CH1 structural domain 162 site sialylated epitope of IgG, the amino acid sequence of the heavy chain variable region is as shown in SEQ ID NO. 1, and the amino acid sequence of the light chain variable region is as shown in SEQ ID NO. 2. The humanized antibody can effectively inhibit the growth, invasion and suspension growth ability of tumor cells, has an obvious anti-tumor effect, and also can inhibit the activation of a c-Met / Wnt signal channel and an FAK signal channel of the tumor cells.
Owner:PEKING UNIV +1
Monoclonal antibody recognizing sialylated sugar chains
The purpose of the present invention is to provide a novel monoclonal antibody having high affinity and that strictly recognizes, as a sugar chain epitope, only a “Siaα2,6Galβ1,4GlcNAc (6′-Sialyl-LacNAc): CDw75” sugar chain structure, being a molecular target for diagnosis of the malignancy of tumors. An anti-CDw75 monoclonal antibody is provided that recognizes “CDw75” sugar chain structures but does not recognize similar sugar chain structures indicated by “Galβ1,4GlcNAc”, “Siaα2,3Galβ1,4GlcNAc”, or “Siaα2,6Galβ1,4Glc”, by using a glycolipid antigen bonding a carrier lipid compound “HOCH2CH (NH—CO—(CH2)22—CH3)—(CH2)9—CH3 (C12L)” developed by the inventors to a “CDw75” sugar chain. The obtained anti-CDw75 monoclonal antibody is an excellent detection drug for B-cell lymphoma, gastric cancer, or colorectal cancer, an excellent diagnostic agent for tumor malignancy, etc., an excellent treatment agent for B-cell lymphoma, gastric cancer, or colorectal cancer, and an excellent prevention / treatment drug for influenza.
Owner:NAT INST OF ADVANCED IND SCI & TECH
Composition used for improving sialyl level of recombinant human type II tumor necrosis factor receptor-antibody fusion protein
ActiveCN106318998AIncrease contentIncreased substrate supplyMicroorganism based processesFermentationMannoseN-Acetylglucosamine
The invention relates to a composition used for improving the sialyl level of a recombinant human type II tumor necrosis factor receptor-antibody fusion protein. The composition comprises galactose (10-100mmol / L), glucosamine (1-50mmol / L), N-acetylmannosamine (1-50mmol / L), N-acetylglucosamine (1-50mmol / L), uracil (1-50mmol / L), tetrahydrate manganese chloride (0.01-1mmol / L), dexamethasone (0.01-1mmol / L) and hydrocortisone (0.01-1mmol / L). After the composition disclosed by the invention is added into a culture medium, the sialyl level of the recombinant human type II tumor necrosis factor receptor-antibody fusion protein produced by a large-scale animal cell culture technology can be obviously improved, so that the stability of the recombinant human type II tumor necrosis factor receptor-antibody fusion protein is improved.
Owner:HISUN BIOPHARMACEUTICAL CO LTD +1
Phenotypic profiling of hepatocellular carcinoma circulating tumor cells for treatment selection
ActiveUS20200182877A1Accurate identificationEfficient captureImmunoglobulins against cell receptors/antigens/surface-determinantsDisease diagnosisOncologyThelial cell
Methods and kits for detecting hepatocellular carcinoma recurrence or metastasis, and of measuring markers of hepatocellular carcinoma, including markers of hepatocellular carcinoma recurrence or metastasis, in a blood sample obtained from a subject by (a) isolating circulating tumor cells (CTCs) by contacting a blood sample obtained from the subject with a set of capture antibodies, wherein the capture antibodies specifically bind asialoglycoprotein receptor (ASGPR), Glypican-3, and epithelial cell adhesion molecule (EpCAM); (b) contacting the isolated CTCs with an antibody that specifically binds vimentin; and (c) measuring the number of vimentin-positive CTC.
Owner:RGT UNIV OF CALIFORNIA
Sialyloligosaccharide-platinum nanoparticle, preparation method and use thereof in immunodetection of influenza virus
The invention relates to a sialyloligosaccharide-platinum nanoparticle, a preparation method and use thereof in immunodetection of influenza virus. The sialyloligosaccharide-platinum nanoparticle is obtained by connecting sialyloligosaccharide having a linker arm to a surface of a platinum nanoparticle by an using S-Pt covalent bond. A immunodetection method in the invention completely avoids using antibodies and enzymes, and has advantages of high stability, easy preparation and acquisition and the like.
Owner:INST OF MICROBIOLOGY - CHINESE ACAD OF SCI
Monoclonal antibody against asialo alpha 1-acid glycoprotein, immunochromatographic strip comprising the monoclonal antibody, and method for diagnosing liver diseases using the immunochromatographic strip
ActiveUS20060177876A1Easily and rapidlyEasy to detectImmunoglobulins against cell receptors/antigens/surface-determinantsDisease diagnosisDiseaseRicinus sanguineus
The present invention relates to a method for diagnosing a liver disease rapidly in an early stage. More particularly, the present invention relates to a monoclonal antibody against asialo α1-acid glycoprotein; a method for diagnosing a liver disease which evaluates asialo α1-acid glycoprotein in a test sample by using said monoclonal antibody; and an diagnostic strip for immunochromatography composed of said monoclonal antibody against asialo α1-acid glycoprotein and Ricinus communis agglutinin (RCA). The diagnostic device of the present invention is convenient to measure the concentration of asialo α1-acid glycoprotein and to diagnose a liver disease rapidly.
Owner:NEOBIODIGM +1
Preparation and application of electrochemiluminescence sensor for detecting sialylated sugar chain antigen KL-6 iridium nanodots
ActiveCN112683968AHigh ECL EfficiencyGood water solubilityChemiluminescene/bioluminescenceNanosensorsInterstitial lung diseaseAntigen
The invention relates to preparation and application of an electrochemiluminescence sensor for detecting sialylated sugar chain antigen KL-6 iridium nanodots, and is characterized in that the iridium nanodots with good water solubility, good biocompatibility and high electrochemiluminescence efficiency are prepared, an antibody labeled iridium nanodot solution is used as a signal probe to develop the label-free electrochemiluminescence immunosensor, the sensor is used for rapid and sensitive detection of the interstitial lung disease marker sialylated sugar chain antigen KL-6, the detection limit is 45 fg / mL, the linear range is 100 fg / mL and 50 ng / mL, and the sensor has the advantages of being high in specificity, good in reproducibility, stable in signal and the like.
Owner:UNIV OF JINAN
Method for diagnosing alzheimer's disease using serum glycoprotein as biomarker
InactiveUS20110076704A1Cleavage of an amyloid precursor proteinHigh activityImmunoglobulins against animals/humansPeptide preparation methodsSerum igeDisease
It is an object of the present invention to detect a change in the metabolism of a glycoprotein having an α2,6-sialyl residue, which is contained in blood, so as to provide an agent and a method for diagnosing sporadic Alzheimer's disease. The present invention provides an agent for diagnosing Alzheimer's disease, which comprises lectin used for detecting an α2,6-sialyl residue-containing glycoprotein.
Owner:RIKEN
Anti-Sialyl Tn chimeric antigen receptors
ActiveUS11279769B2Maintaining proliferationReduce in quantityImmunoglobulins against cell receptors/antigens/surface-determinantsNGF-receptor/TNF-receptor superfamilySialyl LeAAntigen receptors
The invention provides improved compositions for adoptive cell therapies for cancers that express the glycoepitope STn on TAG-72.
Owner:HELIXMITH CO LTD
CTLA-4 antibody and preparation method thereof
PendingCN113024670AImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsHigh mannoseAntiendomysial antibodies
The invention discloses a CTLA-4 monoclonal antibody and preparation and application of the monoclonal antibody. The CTLA-4 monoclonal antibody has the advantages of lower toxicity and better activity. In addition, the CTLA-4 antibody also has low-content high mannose glycoforms and / or low-content sialylated glycoforms so that the half-life period of the antibody is prolonged and / or the immunogenicity is reduced.
Owner:BIO THERA SOLUTIONS LTD
Sialyl transferase variants having neosialidase activity
α2-6-Sialyltransferase (2,6ST) variants having improved α2-6-specific sialidase activity as compared to the native 2,6ST enzymes are described. The variants include GT80 sialyltransferases such as P. damselae Pd2,6ST. Methods for making de-sialylated products and screening sialidase activity are also described.
Owner:RGT UNIV OF CALIFORNIA
Methods for modifying human antibodies by glycan engineering
ActiveUS11377485B2Immunoglobulins against cell receptors/antigens/surface-determinantsFermentationAntiendomysial antibodiesAntibody fragments
Methods for making modified Fc regions of antibodies and antibody fragments, both human and humanized, and having enhanced stability and efficacy, are provided. Antibodies comprising Fc regions with core fucose residues removed, and attached to oligosaccharides comprising terminal sialyl residues, are provided. Antibodies comprising homogeneous glycosylation of Fc regions with specific oligosaccharides are provided. Fc regions conjugated with homogeneous glycoforms of monosaccharides and trisaccharides, are provided. Methods of preparing human antibodies with modified Fc using glycan engineering, are provided.
Owner:ACAD SINIC
Α,2,8-sialyltransferase
InactiveUS7163791B2Increase volumeEfficient purificationBacteriaSugar derivativesSialyltransferaseGanglioside GD3
The invention provides a novel α-2,8-sialyltransferase expressed by a gene cloned from animal cells, a cDNA coding for the α-2,8-sialyltransferase, a method of detecting, or suppressing the production of α-2,8-sialyltransferase by using the cDNA, a recombinant vector containing the DNA as an insert and cells harboring the recombinant vector as well as methods of preparing same. The α-2,8-sialyltransferase of the invention is useful, for example, in the production of carbohydrate chains having a useful physiological activity, for example the ganglioside GD3, and modifications thereof.
Owner:KYOWA HAKKO KIRIN CO LTD
Dual fluorescence imaging method of mucoprotein 1 and sialyl glycosyl thereof and application
ActiveCN111999504AHas dual fluorescence imaging propertiesStrong fluorescent penetrating abilityBiological material analysisBiological testingCancers diagnosisIn vivo
The invention discloses a dual fluorescence imaging method of mucoprotein 1 and sialyl glycosyl thereof and application, and belongs to the technical field of fluorescence imaging and the field of biomedicine. According to the invention, a sialic acid-gold nanostar probe Sia-GNSs and a mucoprotein 1-quantum dot probe MUC1-QDs, which are high in specificity and biocompatibility, are successfully constructed. MUC1 in the MCF-7 cell can be specifically recognized by using the Sia-GNSs and the MUC1-QDs in a combined manner. The nano probe prepared by the invention can realize dual fluorescence imaging and relative quantification of MUC1 protein skeleton and Sia glycosyl thereof in vitro, in vivo and in clinical breast cancer patient tissue samples. The invention provides a simple and effectiveplatform, and has huge potential in clinical cancer diagnosis.
Owner:JIANGNAN UNIV
Proteins binding nkg2d, cd16 and a tumor-associated antigen
PendingCN113164570AImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsCD16Nkg2d receptor
Multi-specific binding proteins that bind NKG2D receptor, CD 16, and a tumor- associated antigen selected from c-MET, KIT, F3, IGF1R, Lewis Y, MUC13, MUC4, MCAM, LRRC32, sialyl-Tn, gpA33, GD3, GM2, EPHA3, TNFRSF10A, TNFSF11, CD74, and PMEL are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
Owner:DRAGONFLY THERAPEUTICS INC
Sialylated fetuin-A as a marker of immunotherapy efficacy
The invention concerns the identification of specific polypeptides, fragments variants thereof which can be used as markers for the efficacy of immunotherapy, particular for predicting responsiveness of a patient to immunotherapy.
Owner:STALLERGENES SA
Antibody and functional fragment thereof
Disclosed are an antibody or a functional fragment thereof binding to 3′-sialyl lactose and comprising a heavy chain variable region which is optionally substituted with 3 or less amino acids and which comprises a CDR sequence consisting of an amino acid sequence ARKNGGLDYAMDY (SEQ ID NO: 3), a polynucleotide encoding the antibody or the functional fragment thereof, an expression vector comprising the polynucleotide, and a test drug for a disease and a pharmaceutical composition comprising the antibody or the functional fragment thereof.
Owner:SUMITOMO CHEM CO LTD
Antibody and functional fragment thereof
Disclosed are: an antibody, which binds to 3'-sialyllactose and contains a heavy chain variable region having a CDR sequence comprising an amino acid sequence ARKNGGLDYAMDY (SEQ ID NO: 3) in which not more than 3 amino acids may be substituted, or a functional fragment thereof; a polynucleotide encoding the antibody or a functional fragment thereof; an expression vector containing the polynucleotide; and a test agent and pharmaceutical composition for treating a disease, which comprise the antibody or a functional fragment thereof.
Owner:SUMITOMO CHEM CO LTD
Sialylated di-Lewis alpha expressed on glycoproteins instead of glycolipids and antibodies thereof as functional cancer targets
ActiveCN108137695BPolypeptide with localisation/targeting motifImmunoglobulin superfamilyAntiendomysial antibodiesSialyl LeA
The present invention relates to the ability to bind sialylated di-Lewis a Isolated specific binding members of the invention, and related therapeutic and pharmaceutical compositions for the treatment of cancer.
Owner:SCANCELL
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com